Patient Stories in PAH: Sequential Therapy in a FC II Patient

Slides:

Advertisements

Similar presentations

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:

Practical Recommendations for COPD:

Exploring Early Combination Therapy in PAH

CLINICAL DILEMMAS IN HEART FAILURE:

Monitoring and Modifying Treatment in PAH

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

A Paradigm Shift in PAH.

An Update on Oral Prostanoids: Advancing Care for PAH?

Goals of Therapy for Patients With UC

Thrombosis, Cancer, and NOACs

Glaucoma Progression.

A CASE CHALLENGE IN HFrEF:

UNDERSTANDING RISK STRATIFICATION IN PAH:

MANAGING GLAUCOMA:.

Modern Strategies for Basal Insulin Use in T2D

The Latest Data on Oral Prostacyclin Therapy in PAH

Insulin/GLP-1 Agonist Combinations

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

All About PAH:.

T2DM and CV Outcomes Trials: A Deep Dive!

PAH Therapy Revisited.

PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence

Improving Risk Assessment and Early Diagnosis in PAH

Updates in Pulmonary Arterial Hypertension

Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy

WHO Clinical Classification of PH Complex Cases in PH.

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Evolving Science of PAH Treatment

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Risk Assessment in PAH.

EHL Technologies in Hemophilia Care

A Better Solution For Cancer Patients With VTE?

2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.

Insulin/GLP-1 Agonist Combinations

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Examining the Latest Evidence in PAH

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

The Importance of Getting the Dose Right in HF

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Oral Prostanoids and PAH

Navigating Treatment Options in PAH

Preventing Clinical Events in PAH

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

PAH and Prostacyclin Pathways in Focus

PAH-Related Morbidity as a Predictor of Mortality

Cancer-Associated Thrombosis

Pulmonary Arterial Hypertension and Connective Tissue Disease

What's New in PAH?.

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Oral Prostacyclin Pathway Agents in PAH

Critical Decision Points in Insomnia

Incorporating Prostacyclins Into Practice

Saving the Day.

Optimal Treatment of PAH

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Prostacyclin Pathway Agents in Action

AMD Therapy: Where Are We Now and Where Are We Going?

Tailoring Therapy in the Newly Diagnosed Patient With CLL

PAH Pathways: What Do the Data Tell Us?”

Binge Eating Disorder.

Clinical Comparisons in CTEPH

What's New in PAH?.

Practical Recommendations for COPD:

Treatment Advances for RA

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

What's New in NOACs in AF?.

Translating Data From Trial to Practice

Presentation transcript:

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Program Goals

Case Study 53-Year-Old Man With IPAH

Case Study History

Case Study (cont) History

Now, 17 Months Later

Repeat RHC Findings

Sequential Combination Therapy Recommendations for WHO FC II PAH Patients

Pharmacologic Agents for PAH 3 Pathways

Rationale for Combination Therapy

GRIPHON

GRIPHON Treatment Effect by Subgroup

GRIPHON Titration and Dosing

Primary Composite Endpoint in Patients Grouped by Prespecified Selexipag Individual Maintenance Dose vs Placebo

Case Summary

Abbreviations